A smorgasbord of challenges face radiology but few present a greater threat than the “invisible radiologist,” said Dr. Gary Glazer, chairman of the Stanford University radiology department, who kicked off the 11th International Symposium on Multidetector-Row CT.
A smorgasbord of challenges face radiology but few present a greater threat than the “invisible radiologist,” said Dr. Gary Glazer, chairman of the Stanford University radiology department, who kicked off the 11th International Symposium on Multidetector-Row CT.
Glazer flashed a four-year-old New York Times story on the screen, an anecdote of a woman who waited weeks to learn the results of a CT scan. The suspicious lesion was noncancerous, but the experience was a nightmare. The story crystallized concerns by Glazer about the invisibility of the radiologist.
“It is quite clear, in a high percentage, as high as 90%, that the patient never speaks with the physician interpreting the scan,” Glazer said. “There has been a huge amount of work undertaken over the last decade at improving efficiency of workflow and developing ideal workstations – but these sorts of questions have all related to the life of the radiologist. The patient has been nowhere in this consideration.”
This must change in the years to come, he said. “If healthcare is to improve, the interaction of radiologist and patients must be optimized,” Glazer said.
Among the other challenges and, by extension, opportunities for radiology is for CT to push the boundaries of biology not so much for diagnostic as therapeutic purposes. Glazer said CT has a role to play in personalized medicine, particularly in helping physicians tailor drug therapy to improve outcomes and reduce costs by focusing on those that are effective. This will be done by moving backwards from the image to the molecular underpinnings of disease by correlating what is seen in radiology to genomics, he said.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.